All genome sequences and their associated metadata used in this study are available on the PATRIC database (<https://www.patricbrc.org/>). Genome IDs for specific strains used are available in [S1 Dataset](#pcbi.1007608.s020){ref-type="supplementary-material"}. All reference sequences used for identifying antimicrobial resistance genes are available in [S2 Dataset](#pcbi.1007608.s021){ref-type="supplementary-material"}.

Introduction {#sec001}
============

The emergence of antimicrobial resistance (AMR) remains a persistent problem in the treatment of bacterial infections. Since the discovery of penicillin in 1928, pathogens have developed resistance to almost all major antibiotics, often within a few years of their introduction \[[@pcbi.1007608.ref001], [@pcbi.1007608.ref002]\]. Advancements in sequencing technology have already yielded hundreds to thousands of publicly-available genome sequences for each major bacterial pathogen \[[@pcbi.1007608.ref003]\], and analyzing this deluge of data will require robust analytic workflows to extract insights on the acquisition of resistance, its genetic basis, and the underlying molecular mechanisms.

AMR prediction models have already been developed from genome sequence collections of many pathogens, such as *Staphylococcus aureus* \[[@pcbi.1007608.ref003], [@pcbi.1007608.ref004], [@pcbi.1007608.ref005]\], *Mycobacterium tuberculosis* \[[@pcbi.1007608.ref004], [@pcbi.1007608.ref006], [@pcbi.1007608.ref007]\], *Salmonella* \[[@pcbi.1007608.ref008], [@pcbi.1007608.ref009]\], *Klebsiella pneumoniae* \[[@pcbi.1007608.ref010], [@pcbi.1007608.ref011]\], and *Neisseria gonorrhoeae* \[[@pcbi.1007608.ref012], [@pcbi.1007608.ref013]\]. However, these approaches are often designed to maximize accuracy in predicting AMR phenotypes, emphasizing their diagnostic capabilities over their capacity to uncover genetic mechanisms for resistance. Many such models are also based on the detection of genes from a curated set of known AMR determinants, rendering them difficult to generalize to different treatments or organisms and unsuitable for discovering novel genes or interactions that drive resistance. Continued reductions in sequencing costs will enable whole genome sequencing (WGS) of these pathogens at an increasing scale, and soon expand the capabilities of statistical approaches beyond the prediction of AMR phenotypes and towards the reliable identification of their genetic determinants. Thus, computational tools developed with both goals of predicting and explaining AMR phenotypes are sorely needed.

The identification of gene-AMR relationships falls under the umbrella of microbial genome-wide association studies (GWAS), which bear many similarities to human GWAS \[[@pcbi.1007608.ref014]\]. However, microbial GWAS methods are still under development as traditional human GWAS methods struggle to generalize to highly clonal datasets without complex adjustments for population structure \[[@pcbi.1007608.ref015], [@pcbi.1007608.ref016], [@pcbi.1007608.ref017]\]. We present here a simple, reference-agnostic, machine learning approach based on pan-genomes for identifying AMR-associated genes using random subspace ensembles (RSEs), previously shown to improve the accuracy of support vector machines trained on high-dimensional biological imaging data \[[@pcbi.1007608.ref018]\]. In contrast to more commonly used bootstrapping ensembles, RSEs aggregate classifiers trained on random subsamples of both the sample set (genomes with associated AMR phenotypes) and the feature set (genes and alleles identified in those genomes). We find this method to both accurately predict AMR phenotypes as well as detect known AMR determinants more reliably than well-known association tests or other ensemble strategies, and use this method to predict novel AMR-linked genes for multiple antimicrobials in *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*.

Results {#sec002}
=======

Selection of genetic features through pan-genome construction {#sec003}
-------------------------------------------------------------

Sets of 288, 456, and 1588 publicly-available genomes for *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*, respectively, were downloaded from PATRIC after filtering by contig count and availability of experimental AMR phenotype data ([S1 Dataset](#pcbi.1007608.s020){ref-type="supplementary-material"}) \[[@pcbi.1007608.ref019]\]. To convert these genome assemblies into fixed feature sets amenable to machine learning, we first constructed a pan-genome for each organism by clustering open reading frames by protein coding sequence into putative genes and classifying each gene as either core (missing in 0--10 genomes), accessory (missing in \>10 genomes, present in \>10 genomes), or unique (present in 1--10 genomes). This 10-genome threshold was selected by identifying when the core genome size stabilizes as the threshold for core gene was gradually relaxed ([S1 Fig](#pcbi.1007608.s001){ref-type="supplementary-material"}). We find that this reference genome-agnostic strategy for gene identification produces pan-genomes consistent with previous pan-genome studies in terms of core-genome size, pan-genome openness, and relationship between gene function and gene frequency (see [S1 Text](#pcbi.1007608.s026){ref-type="supplementary-material"}).

Furthermore, as the causative variation responsible for AMR often exists at the level of individual mutations, we identified and enumerated all observed unique amino acid sequence variants or "alleles" of each gene for each pan-genome ([S1 Table](#pcbi.1007608.s012){ref-type="supplementary-material"}). Individual genomes were encoded based on the presence or absence of core gene alleles and the presence or absence of non-core genes, yielding a binary matrix representation of genetic variation for each pan-genome that is not biased towards a reference genome and encodes both fine-grained allelic variations in the core genome and broader variations in the dispensable genome.

Support vector machine ensembles identify known AMR genes more reliably than common statistical tests from the *S*. *aureus* pan-genome {#sec004}
---------------------------------------------------------------------------------------------------------------------------------------

We focus initially on the *S*. *aureus* pan-genome to test variations of a recently reported support vector machine (SVM) approach \[[@pcbi.1007608.ref006]\], and evaluate their capacity to detect genes from an *a priori* assembled list of known AMR determinants, compared to traditional statistical association tests. We examined six antibiotic treatments against *S*. *aureus* from distinct drug classes for which experimentally measured AMR phenotype data was available, binarized as Susceptible versus Resistant ([S2 Table](#pcbi.1007608.s013){ref-type="supplementary-material"}): ciprofloxacin (fluoroquinolone), clindamycin (lincosamide), erythromycin (macrolide), gentamicin (aminoglycoside), tetracycline (tetracycline), and trimethoprim/sulfamethoxazole (dihydrofolate reductase inhibitor/sulfonamide). For validation, known AMR genes were compiled from literature and the CARD database \[[@pcbi.1007608.ref020]\] ([S2 Dataset](#pcbi.1007608.s021){ref-type="supplementary-material"}), then aligned to the alleles in the pan-genome using blastp to identify those that were present in our dataset. From an initial query of 915 sequences, we detected 32 unique genes associated with AMR for at least one of the six antibiotics, spanning 304 distinct alleles in the *S*. *aureus* pan-genome ([Table 1](#pcbi.1007608.t001){ref-type="table"}). For each allele, the log odds ratio (LOR) for resistance against the corresponding drug and its frequency of occurrence was plotted ([S2 Fig](#pcbi.1007608.s002){ref-type="supplementary-material"}). Aside from rare alleles, we find that alleles of genes involved in either active protection of the drug target or inactivation of the drug molecule almost always have large, positive LORs. However, alleles of genes that may confer AMR via a target site mutation or efflux span a wider range of LORs; this may be due to some site mutants not having mutations that directly confer AMR (in which case, large, negative LORs were observed), and some efflux pumps being individually insufficient for conferring clinically relevant levels of resistance.

10.1371/journal.pcbi.1007608.t001

###### Known AMR genes present in the *S*. *aureus* pan-genome.

![](pcbi.1007608.t001){#pcbi.1007608.t001g}

  Antibiotic         Genes
  ------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ciprofloxacin      *gyrA* \[[@pcbi.1007608.ref021],[@pcbi.1007608.ref022]\], *gyrB* \[[@pcbi.1007608.ref021],[@pcbi.1007608.ref022]\], *parC* \[[@pcbi.1007608.ref021],[@pcbi.1007608.ref022]\], *parE* \[[@pcbi.1007608.ref021],[@pcbi.1007608.ref022]\], *norA* \[[@pcbi.1007608.ref023]\], *norB* \[[@pcbi.1007608.ref023]\], *norC* \[[@pcbi.1007608.ref023]\], *sdrM* \[[@pcbi.1007608.ref023]\], *mdeA* \[[@pcbi.1007608.ref023]\], *qacA* \[[@pcbi.1007608.ref023]\], *mepA* \[[@pcbi.1007608.ref023]\], *mepR* \[[@pcbi.1007608.ref023]\], *mgrA* \[[@pcbi.1007608.ref023]\], *arlR* \[[@pcbi.1007608.ref023]\], *arlS* \[[@pcbi.1007608.ref023]\]
  clindamycin        *ermA* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\], *ermC* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\], *lmrS* \[[@pcbi.1007608.ref026]\], *linA* \[[@pcbi.1007608.ref024]\]
  erythromycin       *ermA* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\], *ermC* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\], *lmrS* \[[@pcbi.1007608.ref026]\], *msrA* \[[@pcbi.1007608.ref027]\], *mphC* \[[@pcbi.1007608.ref024]\]
  gentamicin         *aph(3\')-III* \[[@pcbi.1007608.ref028],[@pcbi.1007608.ref029]\], *ant(4\')-I* \[[@pcbi.1007608.ref028]\], *aac(6\')-aph(2\")* \[[@pcbi.1007608.ref028],[@pcbi.1007608.ref029]\], *ant(6\')-Ia* \[[@pcbi.1007608.ref030]\]
  tetracycline       *tetK* \[[@pcbi.1007608.ref031]\], *tetM* \[[@pcbi.1007608.ref031]\], *tet38* \[[@pcbi.1007608.ref032]\], *norB* \[[@pcbi.1007608.ref023]\], *mgrA* \[[@pcbi.1007608.ref023]\]
  trimethoprim       *folA* \[[@pcbi.1007608.ref033]\], *dfrA* \[[@pcbi.1007608.ref033]\], *dfrG* \[[@pcbi.1007608.ref034]\]
  sulfamethoxazole   *folP* \[[@pcbi.1007608.ref033]\]

To define a baseline level of performance for identifying AMR genes from phenotype associations, we examined how reliably common association tests can detect known AMR genes when sorting by p-value. Examining each antibiotic individually, Fisher's Exact and Cochran-Mantel-Haenszel (CMH) tests were applied between each *S*. *aureus* genetic feature and the AMR phenotypes for that antibiotic, and features were ranked by p-value with fractional ranking to address ties. For the CMH tests, genomes were stratified into clusters generated by applying hierarchical clustering to the genetic feature matrix; the resulting clusters align closely to known subtypes and share similar AMR profiles ([Fig 1](#pcbi.1007608.g001){ref-type="fig"}).

![*S*. *aureus* genomes clustered by shared genetic content compared to known subtypes and antibiotic resistance patterns.\
(a) Genomes clustered using hierarchical clustering with average linkage, based on pairwise Jaccard distances between the sets of genetic features present in each genome. Clusters extracted from this hierarchy align well with (b) experimentally observed resistance patterns and (c) subtype annotations from PATRIC. Antibiotics shown are ciprofloxacin (CIP), clindamycin (CLI), erythromycin (ERY), gentamicin (GEN), sulfamethoxazole/trimethoprim (SXT), and tetracycline (TET).](pcbi.1007608.g001){#pcbi.1007608.g001}

Using the same feature matrix and AMR phenotypes, two types of SVM ensemble were trained for each antibiotic case to classify genomes as susceptible or resistant, composed of 500 SVMs each trained on either 1) a random sample of 80% of genomes and all features to yield a bootstrap ensemble similar to in \[[@pcbi.1007608.ref006]\], or 2) a random sample of 80% of genomes and 50% of features to yield a random subspace ensemble (RSE), an adjustment previously shown to improve the accuracy of SVMs trained on high-dimensional biological data ([Fig 2a](#pcbi.1007608.g002){ref-type="fig"}) \[[@pcbi.1007608.ref018]\]. Analogously, features were ranked by feature weight ([Fig 2b](#pcbi.1007608.g002){ref-type="fig"}).

![Comparison of SVM ensemble approaches and statistical tests for detecting AMR-conferring genes and alleles in *S*. *aureus*.\
(a) Workflow for SVM ensemble approaches. Beginning with genomes from PATRIC, open reading frames (ORFs) are identified and clustered by coding sequence to identify putative genes and alleles. Each genome is encoded based on the presence or absence of each gene and allele to capture genomic variation in the pan-genome as a sparse binary matrix. Genomes and/or features of this matrix are randomly sampled 500 times and used to train SVMs to predict binary AMR phenotype for a single antibiotic from genotype. Weights for each feature are averaged across all models in the ensemble and used to rank features by association to AMR. (b) Associations between known AMR-conferring genomic features and AMR phenotype, as ranked by Fisher's Exact test, Cochran-Mantel-Haenszel test, and four different SVM ensemble types (SVM: ensemble by bootstrapping genomes, SVM-RSE: bootstrapping genomes and features; "random subspace ensemble", SVM-RSE-O: SVM-RSE with oversampling to balance subtypes, SVM-RSE-U: SVM-RSE with undersampling to balance subtypes). Features were ranked either by p-value for statistical tests or by average feature weight for SVM ensembles. Fractional ranking was used for ties. Only features detected by at least one method are shown, colored by rank (green: in top 10, yellow: 11--50, orange: 51--100, gray: \>100). Features shown are either genes or individual alleles (denoted as \<gene\>-\#).](pcbi.1007608.g002){#pcbi.1007608.g002}

We find that both SVM methods consistently identified more known AMR features within both the top 10 and top 50 hits than either statistical test ([Fig 2b](#pcbi.1007608.g002){ref-type="fig"}). For instance, *ermC* and *lmrS* for clindamycin and erythromycin were only detectable by SVM methods, and *aac(6\')-aph(2\")* for gentamicin was detected as ranks 1 and 3 by the two SVM methods, compared to much higher ranks 84.5 and 148 by Fisher's Exact and CMH tests, respectively. Additionally, the RSE approach allowed for known AMR genes to be detected at lower ranks compared to bootstrapping in several cases; notably, *lmrS* for clindamycin and erythromycin was detected more than 70 ranks lower with this adjustment, putting *lmrS* within the top 50 hits in both cases with the random subspace approach. To control for phylogenetic distribution, SVM-RSE was also run with either oversampling (SVM-RSE-O) or undersampling (SVM-RSE-U) of genomes to balance the representation of the clusters used in CMH. However, the impact these controls have on the detection of individual known AMR genes is highly variable and does not suggest an improvement overall ([Fig 2b](#pcbi.1007608.g002){ref-type="fig"}). For instance, SVM-RSE-O is the only approach able to identify *ermA* for clindamycin in the top 10, but loses a *gyrA* allele and two *parC* alleles for ciprofloxacin detected by SVM-RSE. Similarly, SVM-RSE-U improves the ranking of several known AMR genes already in the top 10 when compared to SVM-RSE, but loses *lmrS* from the top 50 for both clindamycin and erythromycin and loses *dfrG* for sulfamethoxazole/trimethoprim entirely. Finally, we note that Fisher's Exact test was able to capture two tetracycline resistance genes (*tetM*, *tet38*) albeit at a high ranking of 83.5, while the other three approaches all identified only *tetK* as rank 1 and neither of the other two. However, Fisher's Exact test suffered from an extremely high number of significant hits with Bonferroni correction to FWER ≤ 0.05 ([S3 Table](#pcbi.1007608.s014){ref-type="supplementary-material"}), most likely due to strong lineage effects driving resistance in which detected features are often markers for a highly resistant subtype rather than true AMR genes \[[@pcbi.1007608.ref015]\]. The CMH test with inferred clusters resulted in a more reasonable amount of significant hits, though in the cases of clindamycin and erythromycin, no genes were found significant even with a less stringent Benjamini-Hochberg correction to FDR ≤ 0.05.

SVM random subspace ensembles identify known AMR genes in *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli* across multiple antibiotics {#sec005}
---------------------------------------------------------------------------------------------------------------------------------------

We applied our SVM-RSE approach to identify AMR genes in the larger *P*. *aeruginosa* and *E*. *coli* pan-genomes, using the same core allele/non-core gene encoding of genomes and focusing on features positively associated with resistance. In addition to the six *S*. *aureus* cases, SVM-RSEs were trained to predict resistance for ten more organism-antibiotic cases: for amikacin, ceftazidime, levofloxacin, and meropenem in *P*. *aeruginosa*, and for amoxicillin/clavulanic acid, ceftazidime, ciprofloxacin, gentamicin, imipenem, and trimethoprim in *E*. *coli*, for a total of 16 organism-antibiotic cases ([S2 Table](#pcbi.1007608.s013){ref-type="supplementary-material"}, [Fig 3a](#pcbi.1007608.g003){ref-type="fig"}).

![Predictive performance of SVM-RSE on 16 organism-antibiotic cases.\
(a) Distribution of AMR phenotypes for each case. Organisms examined are *S*. *aureus* (SA), *P*. *aeruginosa* (PA), and *E*. *coli* (EC). Antibiotics examined are ciprofloxacin (CIP), clindamycin (CLI), erythromycin (ERY), gentamicin (GEN), tetracycline (TET), sulfamethoxazole/trimethoprim (SXT), amikacin (AMK), ceftazidime (CAZ), levofloxacin (LVX), meropenem (MEM), amoxicillin/clavulanic acid (AMC), imipenem (IPM), and trimethoprim (TMP). (b) SVM-RSE performance metrics from 5-fold cross validation. Performance values shown are averages and standard errors from 5-fold cross validation. The left-most column "log2(R/S)" shows the extent of class imbalance, the log2 of the number of resistant genomes divided by the number of susceptible genomes.](pcbi.1007608.g003){#pcbi.1007608.g003}

By examining the highest weighted features in each SVM-RSE, this approach was able to identify known AMR genes among the top 50 hits in 15 out of the 16 cases, with more than half of those hits occurring within the top 10 and at least one known AMR gene found among the top 10 in 13 out of the 16 cases ([Table 2](#pcbi.1007608.t002){ref-type="table"}). Only in the case of *P*. *aeruginosa-*amikacin were no such genes found, in which all aminoglycoside-inactivating enzymes in the pan-genome identified by sequence homology had either modest LORs for resistance or were extremely rare ([S4 Table](#pcbi.1007608.s015){ref-type="supplementary-material"}). In total, 10, 7, and 28 unique AMR genetic features previously described in literature were detected and associated to the correct antibiotic for *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*, respectively.

10.1371/journal.pcbi.1007608.t002

###### Known resistance-conferring genes found by SVM-RSE in *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*.

![](pcbi.1007608.t002){#pcbi.1007608.t002g}

  Organism            Drug   Features   Ranked 1--10                                                                                                                                                                    Ranked 11--50
  ------------------- ------ ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *S*. *aureus*       CIP    2          [*gyrA*]{.ul} \[[@pcbi.1007608.ref021],[@pcbi.1007608.ref022]\], [*parC*]{.ul} \[[@pcbi.1007608.ref021],[@pcbi.1007608.ref022]\]                                                \-
  *S*. *aureus*       CLI    3          *ermC* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\]                                                                                                                        *ermA* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\], *lmrS* \[[@pcbi.1007608.ref026]\]
  *S*. *aureus*       ERY    2          *ermC* \[[@pcbi.1007608.ref024],[@pcbi.1007608.ref025]\]                                                                                                                        *lmrS* \[[@pcbi.1007608.ref026]\]
  *S*. *aureus*       GEN    1          *aac(6\')-aph(2\")* \[[@pcbi.1007608.ref028],[@pcbi.1007608.ref029]\]                                                                                                           \-
  *S*. *aureus*       SXT    1          *dfrG* \[[@pcbi.1007608.ref034]\]                                                                                                                                               \-
  *S*. *aureus*       TET    1          *tetK* \[[@pcbi.1007608.ref031]\]                                                                                                                                               \-
  *P*. *aeruginosa*   AMK    0          \-                                                                                                                                                                              \-
  *P*. *aeruginosa*   CAZ    1          \-                                                                                                                                                                              [*muxC*]{.ul} \[[@pcbi.1007608.ref035]\]
  *P*. *aeruginosa*   LVX    4          [*gyrA*]{.ul} ***(2)*** \[[@pcbi.1007608.ref036]\], [*parC*]{.ul} \[[@pcbi.1007608.ref036]\], *oprD* \[[@pcbi.1007608.ref037]\]                                                 \-
  *P*. *aeruginosa*   MEM    2          *oprD* \[[@pcbi.1007608.ref037]\], *bla*~*OXA-2*~ \[[@pcbi.1007608.ref038]\]                                                                                                    \-
  *E*. *coli*         AMC    2          *bla*~*OXA-1*~ \[[@pcbi.1007608.ref039]\], *bla*~*TEM*~ \[[@pcbi.1007608.ref039]\]                                                                                              \-
  *E*. *coli*         CAZ    4          *bla*~*CTX-M*~ \[[@pcbi.1007608.ref039]\], *bla*~*SHV*~ \[[@pcbi.1007608.ref039]\], *bla*~*CMY*~ \[[@pcbi.1007608.ref039]\]                                                     *bla*~*OXA-1*~ \[[@pcbi.1007608.ref039]\]
  *E*. *coli*         CIP    8          [*parC*]{.ul} \[[@pcbi.1007608.ref040]\], [*gyrA*]{.ul} ***(4)*** \[[@pcbi.1007608.ref040]\]                                                                                    [*parC*]{.ul} \[[@pcbi.1007608.ref040]\], [*parE*]{.ul} \[[@pcbi.1007608.ref040]\], [*mdtA*]{.ul} \[[@pcbi.1007608.ref041]\]
  *E*. *coli*         GEN    6          *aac(3)-IId/III* \[[@pcbi.1007608.ref042],[@pcbi.1007608.ref043]\], *ant(2\")-Ia* \[[@pcbi.1007608.ref043]\], *ant(3\")-Ia* \[[@pcbi.1007608.ref042],[@pcbi.1007608.ref043]\]   *aac(3)-VIa* \[[@pcbi.1007608.ref042],[@pcbi.1007608.ref043]\], *aac(6\')-Ib* \[[@pcbi.1007608.ref042],[@pcbi.1007608.ref043]\], *ant(3\")-Ia* \[[@pcbi.1007608.ref042],[@pcbi.1007608.ref043]\]
  *E*. *coli*         IPM    3          \-                                                                                                                                                                              *bla*~*CTX-M*~ \[[@pcbi.1007608.ref039]\], [*mdtA*]{.ul} \[[@pcbi.1007608.ref041]\], *bla*~*NDM*~ \[[@pcbi.1007608.ref039]\]
  *E*. *coli*         TMP    5          *dfrA1* \[[@pcbi.1007608.ref044]\], *dfrA17* \[[@pcbi.1007608.ref044]\], *dfrA14* \[[@pcbi.1007608.ref044]\]                                                                    *qacE* \[[@pcbi.1007608.ref045]\], *dfrA12* \[[@pcbi.1007608.ref044]\]

For each organism-antibiotic pair, known AMR genes among the top 50 features detected by SVM-RSE are shown. Features referring to individual alleles of a gene are underlined. In the cases of *P*. *aeruginosa*-LVX and *E*. *coli*-CIP, two and four distinct resistant *gyrA* alleles were found in the top 10, respectively. In cases where a gene is mentioned in both the top 10 and rank 11--50 columns, multiple resistant alleles were detected at the different ranks. Antibiotics examined are ciprofloxacin (CIP), clindamycin (CLI), erythromycin (ERY), gentamicin (GEN), sulfamethoxazole/trimethoprim (SXT), tetracycline (TET), amikacin (AMK), ceftazidime (CAZ), levofloxacin (LVX), meropenem (MEM), amoxicillin/clavulanic acid (AMC), imipenem (IPM), and trimethoprim (TMP).

In terms of AMR phenotype prediction, in all 16 cases the individual SVMs of the corresponding SVM-RSE achieved much higher Matthew's correlation coefficients (MCCs) on the test set when trained on the true data compared to data where AMR phenotypes were randomly permuted, suggesting that the associations learned were not due to noise ([S3 Fig](#pcbi.1007608.s003){ref-type="supplementary-material"}). As a whole, the SVM-RSE achieved accuracies ranging from 79.3% to 99.5%, MCCs ranging from 0.394 to 0.952, and area under curves (AUCs) ranging 0.790 to 1.0 on the test set when averaged across 5-fold cross validation experiments ([Fig 3b](#pcbi.1007608.g003){ref-type="fig"}, [S4 Fig](#pcbi.1007608.s004){ref-type="supplementary-material"}). The average precision and recall ranged from 0.624 to 0.995 and 0.481 to 0.990, respectively ([Fig 3b](#pcbi.1007608.g003){ref-type="fig"}). Across these metrics, 6 of 7 problematic cases were either 1) *P*. *aeruginosa* cases, which involve a notably larger genome than the other two organisms and thus present more challenging prediction problems, or 2) strongly class-imbalanced cases (*S*. *aureus*-clindamycin, *S*. *aureus*-erythromycin), though other strongly class-imbalanced cases performed well (*S*. *aureus*-ciprofloxacin, most *E*. *coli* cases). The final problematic case of *E*. *coli-*AMC is reasonably well balanced and may point to the challenge of predicting resistance for combination therapies of drugs with interacting mechanisms. Nonetheless, the models with the highest predictive performance were not necessarily those with the best detection of known AMR determinants and vice versa, which highlights the need for AMR prediction models to be evaluated both in terms of prediction performance and biological relevance.

Finally, we examined whether these top hits are robust to the core gene threshold used to determine which features of the pan-genome are encoded at the gene level and which are encoded at the allele level. Compared to our original threshold of designating all genes missing in no more than 10 genomes as core genes, we also encoded each pan-genome using two relative core gene thresholds: genes missing in no more than 2% or 10% of all genomes. After repeating the SVM-RSE workflow with these alternate pan-genome representations, the set of the top 50 resistance-associated and top 50 susceptibility-associated was reasonably conserved between all thresholds. Across all organism-antibiotic cases, the average Jaccard similarity of selected features was 0.744 when comparing thresholds of 10 vs 10%, and 0.818 when comparing thresholds of 10 vs 2% ([S5 Fig](#pcbi.1007608.s005){ref-type="supplementary-material"}).

Assessment of bias in features selected by SVM random subspace ensembles {#sec006}
------------------------------------------------------------------------

We explored two potential biases in the features selected by SVM-RSE: whether there is a preference for genes with low versus high sequence variability, or for chromosomally versus plasmid encoded genes. First, as our approach encodes core genes at the allele level, we examined whether sequence variability impacts the selection of core gene alleles. Within each pan-genome, the number of unique alleles ("allele count") for each core gene was computed, and for each organism-antibiotic case, the allele count distribution of the genes corresponding to selected core gene alleles was compared to that of all core genes ([S6a and S6b Fig](#pcbi.1007608.s006){ref-type="supplementary-material"}). Across all cases, there is a consistent but modest bias towards selecting core genes with higher sequence variability. However, even in the cases with the largest difference in mean allele count, the allele count distribution for selected core features is nearly indistinguishable from that of all core genes ([S6c--S6e Fig](#pcbi.1007608.s006){ref-type="supplementary-material"}).

Second, we examined whether SVM-RSE is capable of selecting non-core genes that are plasmid encoded. Contigs from all genome assemblies were identified as plasmid or chromosomal based on similarity to known plasmids on PLSDB \[[@pcbi.1007608.ref046]\], and genes with a majority of their alleles located on plasmid contigs were labeled as plasmid encoded genes. For each organism-antibiotic case, the number of selected non-core plasmid and chromosomal genes was compared to that of all non-core genes ([S5 Table](#pcbi.1007608.s016){ref-type="supplementary-material"}). SVM-RSE selected plasmid genes in 10/16 cases, with eight cases showing enrichment for plasmid genes. The six cases in which plasmid genes were not selected fall into two categories: 1) involving fluoroquinolones (ciprofloxacin, levofloxacin), for which resistance is primarily mediated by mutations in chromosomal genes *gyrA* and *parC*, or 2) involving *P*. *aeruginosa*, for which a relatively small fraction of non-core genes could be identified as plasmid encoded (1.3%, compared to 4.1% of *S*. *aureus* and 3.0% for *E*. *coli*). Overall, the SVM-RSE approach for identifying AMR-associated genetic features appears to be robust to sequence variability when selecting core gene alleles, as well as sensitive to plasmid genes when selecting non-core genes.

SVM random subspace ensembles specify the space of *gyrA* and *parC* mutations associated with fluoroquinolone resistance {#sec007}
-------------------------------------------------------------------------------------------------------------------------

We examined resistance to fluoroquinolones (FQs) to compare AMR patterns in different organisms against the same drug class. For all three organisms, the SVM-RSE approach successfully detected at least one allele from both of the two established targets of FQs, *gyrA* and *parC*, within both the top 10 resistance-associated genetic features and the top 10 susceptibility-associated genetic features. All *gyrA* and *parC* alleles that the SVM-RSE associated with resistance bore substitutions previously known to confer resistance to FQs, while those that the model associated with susceptibility had no such known mutations ([Table 3](#pcbi.1007608.t003){ref-type="table"}). Additionally, there were no uncharacterized mutations among the resistance-associated alleles that were not also present in a susceptibility-associated allele, which suggests that FQ resistance attributable to *gyrA* and *parC* may be limited to a narrow space of mutations, even across multiple organisms. Upon examining all *gyrA* and *parC* alleles, we find that resistance conferred by individual *gyrA* alleles is not dependent on a specific *parC* allele or vice versa; the LOR for resistance of any given *gyrA/parC* allele pair is not larger than that of the corresponding *gyrA* or *parC* alleles individually ([S7 Fig](#pcbi.1007608.s007){ref-type="supplementary-material"}). By this metric, there were also no strong pairwise epistatic effects apparent between any of the top 10 resistance-associated hits in all three organisms ([S8 Fig](#pcbi.1007608.s008){ref-type="supplementary-material"}).

10.1371/journal.pcbi.1007608.t003

###### Alleles of *gyrA* and *parC* associated with fluoroquinolone resistance detected by SVM-RSE.

![](pcbi.1007608.t003){#pcbi.1007608.t003g}

  Organism                                                          Feature     \# Res.   \# Sus.   Mutations
  ----------------------------------------------------------------- ----------- --------- --------- -------------------------------------------------------------------------------------------------------------------------------
  [*Alleles associated with fluoroquinolone resistance*]{.ul}                                       
  *S*. *aureus*                                                     *gyrA-18*   119       0         [**S84L**]{.ul} \[[@pcbi.1007608.ref047],[@pcbi.1007608.ref048]\], D402E, T457A, V598I, Δ815, T818E, Δ824, Δ825, E859V, E886D
  *S*. *aureus*                                                     *parC-17*   113       0         [**S80F**]{.ul} \[[@pcbi.1007608.ref048]\], F410Y
  *P*. *aeruginosa*                                                 *gyrA-4*    82        2         [**T83I**]{.ul} \[[@pcbi.1007608.ref049],[@pcbi.1007608.ref050]\]
  *P*. *aeruginosa*                                                 *gyrA-15*   18        1         [**T83I**]{.ul} \[[@pcbi.1007608.ref049],[@pcbi.1007608.ref050]\], Δ909, Δ910
  *P*. *aeruginosa*                                                 *parC-2*    78        1         [**S87L**]{.ul} \[[@pcbi.1007608.ref049],[@pcbi.1007608.ref050]\]
  *E*. *coli*                                                       *gyrA-5*    66        1         [**S83L**]{.ul}**,** [**D87N**]{.ul} \[[@pcbi.1007608.ref022],[@pcbi.1007608.ref040]\]
  *E*. *coli*                                                       *gyrA-6*    15        0         [**S83L**]{.ul}**,** [**D87N**]{.ul}, \[[@pcbi.1007608.ref022],[@pcbi.1007608.ref040]\] D678E, A828S
  *E*. *coli*                                                       *gyrA-9*    157       2         [**S83L**]{.ul}**,** [**D87N**]{.ul}, \[[@pcbi.1007608.ref022],[@pcbi.1007608.ref040]\] A828S
  *E*. *coli*                                                       *gyrA-14*   27        0         [**S83L**]{.ul}**,** [**D87N**]{.ul}, \[[@pcbi.1007608.ref022],[@pcbi.1007608.ref040]\] D678E
  *E*. *coli*                                                       *parC-6*    46        2         [**S80I**]{.ul} \[[@pcbi.1007608.ref022],[@pcbi.1007608.ref040]\]
  [*Alleles associated with fluoroquinolone susceptibility*]{.ul}                                   
  *S*. *aureus*                                                     *gyrA-22*   2         4         D402E, T457A, V598I, Δ815, T818E, Δ824, Δ825, E859V, E886D
  *S*. *aureus*                                                     *parC-1*    0         12        F410Y
  *P*. *aeruginosa*                                                 *gyrA-1*    23        115       \-
  *P*. *aeruginosa*                                                 *gyrA-6*    4         39        Δ909, Δ910
  *P*. *aeruginosa*                                                 *parC-1*    52        137       \-
  *E*. *coli*                                                       *gyrA-0*    3         637       D678E, A828S
  *E*. *coli*                                                       *gyrA-1*    1         152       D678E
  *E*. *coli*                                                       *gyrA-22*   2         179       \-
  *E*. *coli*                                                       *parC-1*    1         250       \-
  *E*. *coli*                                                       *parC-2*    7         475       D475E

Alleles of *gyrA* and *parC* among the top 10 hits associated with either resistance or susceptibility by SVM-RSE were characterized based on mutations relative to the corresponding gene in a reference genome for each organism: NC_002745.2 for *S*. *aureus* (N315), NC_022516.2 for *P*. *aeruginosa* (PAO1), U00096.3 for *E*. *coli* (K12 MG1655). Allele-specific mutations are shown, with known resistance-conferring mutations shown in bold and underlined. Each allele's frequency among resistant (Res.) and susceptible (Sus.) genomes are shown.

Characterization of candidate novel AMR genes {#sec008}
---------------------------------------------

In order to reduce the set of top resistance-associated genetic features to a smaller number of higher confidence AMR gene candidates, we filtered the top 10 hits for each organism-antibiotic case based on existing annotations and the level of sequence variability in each hit's assigned gene cluster (see [Methods](#sec010){ref-type="sec"}). This yielded 25 candidate AMR-associated features which were further characterized by domain annotations from InterPro \[[@pcbi.1007608.ref051]\] ([Table 4](#pcbi.1007608.t004){ref-type="table"}). In 9 out of the 13 core gene allele candidates, only a subset of the mutations present in the predicted AMR-conferring allele were actually enriched for resistance; those mutations were found to be present in known domains of their corresponding core gene and are strong candidates to be AMR-conferring ([Fig 4](#pcbi.1007608.g004){ref-type="fig"}).

10.1371/journal.pcbi.1007608.t004

###### Novel resistance-conferring gene candidates predicted by SVM-RSE.

![](pcbi.1007608.t004){#pcbi.1007608.t004g}

  ----------------------------------------------------- ---------- --------------- --------- --------- --------------------------------------------------------------------------------- -------------------------------------------------
  [*Predicted AMR-conferring core gene alleles*]{.ul}                                                                                                                                    
  **Organism**                                          **Drug**   **Gene**        **R/S**   **LOR**   **AMR mutations**                                                                 **Mutation location(s)**
  *S*. *aureus*                                         ERY        *hflX*          135/0     8.8       Wildtype                                                                          \-
  *S*. *aureus*                                         GEN        SA_RS03845      134/0     13.5      S409N                                                                             ABC transporter-like domain
  *S*. *aureus*                                         GEN        *metS*          134/0     13.5      T506N, E541K                                                                      Anticodon-binding domain
  *S*. *aureus*                                         GEN        *oppD*          134/0     13.5      S68N, N132K                                                                       ABC transporter-like domain
  *S*. *aureus*                                         GEN        *comGD*         134/0     13.5      D126Y                                                                             ComG operon protein 4 family (non-cytoplasmic)
  *S*. *aureus*                                         GEN        *ahpF*          134/0     13.5      E38D, S44T, N112K, S422N, K448N                                                   Thioredoxin-like DSF; FAD/NAD(P)-binding domain
  *S*. *aureus*                                         TET        *secE*          131/2     8.7       G60R                                                                              C-terminus
  *S*. *aureus*                                         TET        SA_RS11525      131/2     8.7       H127Y                                                                             \-
  *S*. *aureus*                                         TET        SA_RS10745      130/2     8.5       K641Q                                                                             RNA-binding domain S1
  *S*. *aureus*                                         TET        *kdpB2*         130/2     8.5       P26L                                                                              P-type ATPase TM DSF
  *P*. *aeruginosa*                                     CAZ        PA5359          48/1      6.3       DEL 1--24                                                                         N-terminal signal peptide
  *P*. *aeruginosa*                                     CAZ        PA1414          48/1      6.3       DEL 1--33                                                                         N-terminus
  *P*. *aeruginosa*                                     CAZ        PA1942          48/1      6.3       DEL 1--32                                                                         N-terminus
  [*Predicted AMR-conferring accessory genes*]{.ul}                                                                                                                                      
  **Organism**                                          **Drug**   **Accession**   **R/S**   **LOR**   **Predicted protein/features**                                                    
  *S*. *aureus*                                         CLI        WP_000664727    71/5      0.7       Plasmid replication protein, RepL                                                 
  *S*. *aureus*                                         GEN        WP_000134308    134/1     11.6      Acyl-CoA N-acyltransferase, GNAT domain                                           
  *S*. *aureus*                                         TET        WP_031824444    123/2     7.8       Replication initiation factor                                                     
  *E*. *coli*                                           AMC        WP_097223430    26/5      3.5       Bacterial toxin RNase RnlA/LsoA                                                   
  *E*. *coli*                                           AMC        WP_000710826    26/5      3.5       Antitoxin RnlB/LsoB                                                               
  *E*. *coli*                                           AMC        WP_000774834    25/11     2.4       Plasmid stability protein StbB                                                    
  *E*. *coli*                                           CAZ        WP_001620093    13/33     2.1       NagB/RpiA transferase-like, DeoR-type HTH domain, DeoR C-terminal sensor domain   
  *E*. *coli*                                           CAZ        WP_000243817    82/15     7.1       RmlC-like cupin fold metalloprotein, WbuC family                                  
  *E*. *coli*                                           CIP        WP_001304218    262/386   3.9       Nucleoside triphosphate hydrolase, AAA domain                                     
  *E*. *coli*                                           GEN        WP_001330846    44/1      8.5       TM protein                                                                        
  *E*. *coli*                                           IMP        WP_001310177    2/25      2.0       PyrBI operon leader peptide                                                       
  *E*. *coli*                                           TMP        WP_000082530    59/9      4.1       Mercury transport protein MerC                                                    
  ----------------------------------------------------- ---------- --------------- --------- --------- --------------------------------------------------------------------------------- -------------------------------------------------

Selected AMR-conferring core gene alleles and accessory genes predicted by SVM-RSE, for *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*. For core gene alleles, genes names and mutations are defined relative to the reference genomes N315 (NC_002745.2) for *S*. *aureus*, PAO1 (NC_002516.2) for *P*. *aeruginosa*, and K12 MG1655 (U00096.3) for *E*. *coli*. The number of resistant (R) vs. susceptible (S) genomes are shown for each feature. Log2 odds ratios (LORs) were computed using weighted pseudocounts to account for zeroes in the contingency table (see [Methods](#sec010){ref-type="sec"} for details). Protein features and domains were annotated with either InterPro (for core gene alleles) or InterProScan (for accessory genes). Abbreviations not originally in InterPro annotations are DSF (domain superfamily) and TM (transmembrane).

![Characterization of mutations in four predicted AMR-conferring alleles in *S*. *aureus*.\
For each of the predicted AMR-associated genes (a) *kdbB*, (b) SA_RS10745, (c) *oppD* and (d) *ahpF*, the AMR phenotype distributions and locations relative to InterPro structural domains are shown for individual mutations. Mutations in the predicted AMR-associated allele are in orange, while all other mutations observed for that gene are in black (only mutations in at least 5 genomes are shown). For *kdbB*, the first five annotations in light blue are associated with P-type ATPase. Abbreviations include superfamily (SF), domain superfamily (DSF), nucleoside triphosphate hydrolase (NTH), ATP-binding cassette transporter (ABCt), pyridine nucleotide-diphosphate oxidoreductase (PNDOR), and alkyl hydroperoxide reductase (AHPR), in addition to those used in InterPro annotations.](pcbi.1007608.g004){#pcbi.1007608.g004}

We note that a few of the predicted core gene alleles are of genes previously associated to resistance against the corresponding antibiotic, if not necessarily in the target organism or mechanistically established. For instance, an HflX-like protein is known to confer resistance in erythromycin in *Listeria monocytogenes* through ribosome recycling \[[@pcbi.1007608.ref052]\], and it is possible that the *hflX* gene discovered here may similarly confer resistance in *S*. *aureus*. In *Helicobacter pylori*, *oppD* was found to be significantly induced by gentamicin exposure \[[@pcbi.1007608.ref053]\]. For *ahpF*, overexpression is known to increase the minimum inhibitory concentration (MIC) for streptomycin (another aminoglycoside) \[[@pcbi.1007608.ref054]\], and has also been linked to increased multi-drug resistance through increased defense against oxidative stress in *E*. *coli* \[[@pcbi.1007608.ref055]\]. Finally, WP_000664727, probable *repL*, has been associated with the replication of staphylococcal resistance plasmids \[[@pcbi.1007608.ref056]\]. Sequences and annotations for these features, as well as for all top 50 hits for all organisms-antibiotic cases are available in [S3](#pcbi.1007608.s022){ref-type="supplementary-material"} and [S4 Datasets](#pcbi.1007608.s023){ref-type="supplementary-material"}, respectively.

Discussion {#sec009}
==========

As the number of publicly-available genome sequences for bacterial pathogens continues to grow, there is an increasing need to develop computational methods capable of discerning insights about antimicrobial resistance at scale. To leverage these highly diverse, genomic datasets, we have developed a reference strain-agnostic workflow based on pan-genomes for building robust machine learning models capable of predicting AMR phenotypes as well as identifying their genetic determinants. Our SVM-RSE approach was able to detect known resistance genes in three microbial pathogens (*S*. *aureus*, *P*. *aeruginosa* and *E*. *coli)* more reliably than common association tests, while achieving prediction accuracies competitive with previous machine learning approaches.

Three pan-genomes were constructed from 288 *S*. *aureus*, 456 *P*. *aeruginosa*, and 1,588 *E*. *coli* genomes, and the genetic diversity observed in each species is consistent with what was previously known of each pathogen. Upon integration of AMR profiling data, we found that our SVM-RSE approach effectively identifies established resistance determinants. SVM-RSE detected twice as many known AMR genes than both Fisher's Exact and CMH tests for *S*. *aureus*, and was able to detect at least one known AMR gene in 15 of 16 organism-antibiotic cases, spanning a total of 45 known AMR associations identified across all three pathogens. Though none of the methods were comprehensive in their detection of all known AMR genes in the pan-genome, the SVM-RSE appears to be the most reliable at detecting those genes for a diverse array of antibiotic classes. We suspect that the success of this approach may be attributable to the following properties: 1) SVMs by design are capable of capturing structure among multiple features, opposed to independent, bivariate association tests, 2) using an ensemble trained on random genome subsets can more robustly determine important features when the feature set is much larger than the sample set, 3) subsampling features introduces training cases where resistance must be learned without the dominant AMR determinant, which often washes out signal from weaker determinants \[[@pcbi.1007608.ref003],[@pcbi.1007608.ref006]\], and 4) genes selected by SVM-RSE are neither biased by their extent of sequence variability nor by whether they are plasmid or chromosomally encoded.

The differences in detection rates between cases are partially due to the properties of their corresponding datasets. Generally, more known AMR genes were detected when both a large number of resistant and susceptible genomes were available; the difficult case of *P*. *aeruginosa*-ceftazidime had only 74 AMR profiles, and cases from the larger *E*. *coli* dataset typically performed better, with the exception of *E*. *coli*-imipenem in which only 23 genomes were resistant. In the third problematic case, *P*. *aeruginosa*-amikacin, AMR profiles were well balanced, but known AMR-conferring genes were rare and/or had modest LORs for resistance, resulting in a more challenging feature selection problem. We also note that while benchmarking with *S*. *aureus* genomes, the model performed equally well even with aggressive undersampling to evenly represent different lineages. This suggests that genetically "redundant" genomes in a pan-genome may be uninformative with respect to AMR. Finally, in all cases the prediction performances of both individual SVMs and SVM ensembles were high and comparable to previous machine learning approaches, independent of their ability to detect known AMR genes. This result comes as a warning that the raw performance of an AMR-prediction model may have little to do with its capacity to learn real AMR mechanisms.

In a deeper analysis of FQ resistance, we found that the top *gyrA* and *parC* alleles associated with resistance or susceptibility by SVM-RSE segregate perfectly by the presence or absence of known AMR-conferring mutations. The top resistance alleles also bore no uncharacterized mutations that were not also present in susceptible alleles, and no notable epistatic interactions between *gyrA* and *parC* allele pairs or any other pairs of predicted AMR-conferring features could be found. It is possible that the mutational landscape for FQ resistance may be relatively smooth and simple, and FQ resistance may be reliably predicted with simpler techniques; however, such hypotheses will be challenging to validate without more detailed measures of resistance beyond binary AMR phenotypes, such as minimum inhibitory concentrations. Extending this analysis to other predicted hits for all antibiotics identified 25 candidate AMR-conferring genetic features, of which several have evidence in other organisms to be involved in antibiotic-related responses, if not directly contributing to resistance.

Ultimately, by shifting the focus of evaluation from prediction accuracy to biological relevance, our framework more honestly expresses the level of confidence one may have in the generalizability of a machine-learning approach. We find that at the current scale of pathogen sequencing and profiling, our workflow is well-suited for not just predicting AMR profiles, but also identifying genetic features known to confer resistance. The inherent flexibility of this approach opens it up to many improvements to expand the range of biological phenomena the models may draw upon to explain AMR; the incorporation of non-coding genetic features, integration of annotations into the learning process, or implementation of more sophisticated resampling and model aggregation strategies are just a few potential extensions of this work. The continued development of the techniques developed here may eventually be used to systematically extract confident explanations of resistance from pan-genomic datasets to robustly inform responses to the growing AMR threat.

Materials and methods {#sec010}
=====================

Genome selection and pan-genome assembly {#sec011}
----------------------------------------

For constructing the *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli* pan-genomes, genomes on PATRIC \[[@pcbi.1007608.ref019]\] were filtered to those that met the following criteria: 1) at least one experimentally measured AMR phenotype (MIC, disk diffusion, agar dilution, Vitek2) is associated with the genome on PATRIC, 2) sequence data is not plasmid-only, and 3) there are at most 100 contigs for *S*. *aureus* assemblies or at most 250 contigs for *P*. *aeruginosa* (for *E*. *coli*, contig filtering was not applied, and only 4 out of 1588 genome assemblies had more than 250 contigs). Genome IDs for selected genomes are available in [S1 Dataset](#pcbi.1007608.s020){ref-type="supplementary-material"}. PATRIC genome annotations were used to construct pan-genomes using CD-Hit v4.8.1 \[[@pcbi.1007608.ref057]\]. The sequence identity threshold was set at 0.8 and the word length was set to the default of 5.

For each pan-genome, the number of genomes each gene cluster was observed in was computed. The number of core genes was calculated from an increasingly relaxed threshold for core gene, i.e. the maximum number of genomes allowed to be missing a core gene; in all three cases the core-genome size stabilizes by a threshold of 10, which is the threshold used to identify core genes in all subsequent analyses ([S1 Fig](#pcbi.1007608.s001){ref-type="supplementary-material"}), and symmetrically to identify unique genes (i.e. genes present in no more than 10 genomes). Within each pan-genome, the unique amino acid sequence variants or "alleles" of each gene were enumerated ([S1 Table](#pcbi.1007608.s012){ref-type="supplementary-material"}).

Mathematical representation of pan-genomes and AMR phenotypes {#sec012}
-------------------------------------------------------------

For each pan-genome, each genome was encoded as a binary vector, based on the presence or absence of every gene cluster and every allele of every gene cluster observed for that organism; this yielded a sparse binary matrix encoding the genetic content at both the gene and allele level ([Fig 2a](#pcbi.1007608.g002){ref-type="fig"}). The number of features was reduced by only analyzing core genes at the allele level, and analyzing non-core genes at the gene level. For each antibiotic, experimental AMR phenotypes were converted to binary vectors by directly converting raw PATRIC AMR annotations "Susceptible" to 0 and both "Resistant" and "Intermediate" to 1. The distribution of binarized phenotypes, typing methods, and typing standards associated with these annotations are in [S2 Table](#pcbi.1007608.s013){ref-type="supplementary-material"}.

Curation of known AMR genes in the *S*. *aureus* pan-genome {#sec013}
-----------------------------------------------------------

Known AMR genes against antibiotics examined for *S*. *aureus* were compiled from literature and the CARD database, retrieved on November 26, 2018 \[[@pcbi.1007608.ref020]\]. CARD entries were filtered down to those referencing any of the antibiotics examined (ciprofloxacin, clindamycin, erythromycin, gentamicin, trimethoprim, sulfamethoxazole, tetracycline) or their drug classes (fluoroquinolone, lincosamide, macrolide, aminoglycoside, trimethoprim, sulfonamide, tetracycline). Representative protein sequences for these genes were taken from either UniProt or CARD ([S2 Dataset](#pcbi.1007608.s021){ref-type="supplementary-material"}) and were aligned to the alleles in the *S*. *aureus* pan-genome using blastp. Hits with an e-value below 10^−50^ and identity \>90% were treated as true AMR determinants.

Curated AMR genes were classified into four broad mechanistic categories ([S2a Fig](#pcbi.1007608.s002){ref-type="supplementary-material"}): 1) Mutant Site, genes that are direct targets to a given drug that can acquire AMR-conferring mutations, 2) Efflux, genes involved in efflux pumps or regulation of efflux pumps, 3) Modifies Site, genes that protect the direct targets of a given drug, such as by ribosomal modification, and 4) Modifies Drug, genes that cleave, modify, or otherwise inactivate the drug molecule. The frequency and LOR for alleles of curated AMR genes were plotted ([S2b and S2c Fig](#pcbi.1007608.s002){ref-type="supplementary-material"}). As most such alleles were very rare and observed AMR phenotypes for many drugs were highly biased towards resistant cases, a modified form of LOR with weighted pseudocounts was computed to more accurately capture the extent of enrichment and address frequent zeroes in contingency tables $$LOR = \text{log}_{2}\left( \frac{\left( {AR + \frac{R}{R + S}} \right)\left( {NS + \frac{S}{R + S}} \right)}{\left( {AS + \frac{S}{R + S}} \right)\left( {NR + \frac{R}{R + S}} \right)} \right),\begin{matrix}
{R = AR + NR} \\
{S = AS + NS} \\
\end{matrix}$$ where AR is the number of resistant genomes with the allele, AS is the number of susceptible genomes with the allele, NS is the number of susceptible genomes without the allele, and NR is the number of resistant genomes without the allele. This adjustment has the following properties: 1) an allele that is not observed (AR = AS = 0) has a non-informative LOR of 0, 2) a universal allele observed in all genomes (NS = NR = 0) has a non-informative LOR of 0, and 3) the total adjustment to the contingency table is 2, which is common for other pseudocounts strategies for addressing contingency tables with zeroes, such as adding 0.5 to all cells.

Comparison of statistical tests and SVM ensemble models for predicting AMR determinants in *S*. *aureus* {#sec014}
--------------------------------------------------------------------------------------------------------

For the *S*. *aureus* pan-genome, Fisher's Exact test and Cochran-Mantel-Haenszel's test were applied between each antibiotic and genetic feature. For CMH, genome subgroups were determined through hierarchical clustering on the genetic feature matrix, implemented in SciPy using pairwise Jaccard distances and average linkage; these clusters were found to be consistent with metadata regarding genome subtype ([Fig 1](#pcbi.1007608.g001){ref-type="fig"}). The two smallest clusters were also treated as a single subgroup for CMH testing. Features were filtered based on significance after either a Bonferroni correction (FWER ≤ 0.05) or Benjamini-Hochberg correction (FDR ≤ 0.05) ([S3 Table](#pcbi.1007608.s014){ref-type="supplementary-material"}), then ranked by p-value with fractional ranking for ties.

For each antibiotic, four different types of SVM ensembles of 500 SVMs each were trained to predict AMR phenotype from the *S*. *aureus* genetic feature matrix, using different resampling strategies ([Fig 2a](#pcbi.1007608.g002){ref-type="fig"}). Within an ensemble, each of the 500 constituent models were trained using one of the following sampling strategies:

1.  [SVM]{.ul}: Random subsets of 80% of genomes.

2.  [SVM-RSE]{.ul}: Random subspaces with 80% of genomes and 50% of features.

3.  [SVM-RSE-U]{.ul}: From each hierarchical clustering subgroup, randomly sample n genomes, where n = 80% of the size of the smallest cluster. Randomly select 50% of features.

4.  [SVM-RSE-O]{.ul}: From each hierarchical clustering subgroup, randomly sample n genomes, where n = 80% of the size of the largest cluster. Randomly select 50% of features.

SVMs were implemented in scikit-learn, using square hinge loss weighted by class frequency to address class imbalance issues. L1 regularization was included to enforce sparsity for feature selection. For each organism-antibiotic case, genomes without AMR phenotype data were ignored. Features were ranked based on the average feature weight across all SVMs in a given ensemble; in cases where features were subsampled, a feature's average weight was calculated from only SVMs that had access to that feature. For each antibiotic, this yielded a list of top hits associated with resistance (largest positive weights/top ranking features) and a list of top hits associated with susceptibility (largest negative weights/bottom ranking features). Both statistical tests and the four SVM ensemble types were compared based on the number and rank of *a priori* curated AMR determinants detected ([Fig 2b](#pcbi.1007608.g002){ref-type="fig"}).

Application of SVM-RSE to predict AMR determinants in *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli* {#sec015}
-------------------------------------------------------------------------------------------------------

The SVM-RSE approach described earlier was applied to a total of 16 organism-antibiotic cases across the three organisms to identify genetic features associated with AMR from experimentally observed AMR phenotypes ([Fig 3a](#pcbi.1007608.g003){ref-type="fig"}). For each case, after training an SVM-RSE on the organism's genetic feature matrix and antibiotic's AMR phenotype vector, the top 50 hits associated with resistance were assessed for known AMR determinants and verified through a literature search ([Table 2](#pcbi.1007608.t002){ref-type="table"}). In examining the *P*. *aeruginosa-*amikacin case, known aminoglycoside-modifying enzymes were identified in the pan-genome using the same process for curating *S*. *aureus* AMR genes ([S4 Table](#pcbi.1007608.s015){ref-type="supplementary-material"}). LORs were computed using the method as for the curated *S*. *aureus* AMR genes.

To assess the "null" level of predictive performance, another SVM-RSE was trained for each organism-antibiotic case in which AMR phenotypes were randomly shuffled. For both the original and permuted ensembles, the performance of each of their 500 constituent SVMs was evaluated by computing the Matthew's correlation coefficients (MCCs) on out-of-bag samples, or genomes not used for training ([S3 Fig](#pcbi.1007608.s003){ref-type="supplementary-material"}). To assess the overall predictive performance of the ensemble, the SVM-RSE approach was treated as a voting classifier, in which the SVM-RSE prediction is the majority prediction of its 500 constituent SVMs. 5-fold cross validation experiments with the SVM-RSE were conducted for each organism-antibiotic case, and the average and standard error of the accuracy, MCC, precision, recall, and area under receiver operating curve (AUROC) for the testing set across all folds were computed ([Fig 3b](#pcbi.1007608.g003){ref-type="fig"}). ROC curves for each fold were also computed ([S4 Fig](#pcbi.1007608.s004){ref-type="supplementary-material"}).

Assessing stability of SVM-RSE selected features for different core gene thresholds {#sec016}
-----------------------------------------------------------------------------------

The core genome of each pan-genome was defined using three thresholds: the set of genes missing in 1) no more than 10 genomes (default), 2) no more than 2% of all genomes, and 3) no more than 10% of all genomes. These core gene thresholds were used to encode each pan-genome in terms of its core gene alleles and non-core genes as described earlier, yielding three distinct matrices per pan-genome (i.e. the genome by gene and allele matrix in [Fig 2a](#pcbi.1007608.g002){ref-type="fig"}). The SVM-RSE analysis was repeated for each pan-genome matrix to predict AMR-associated features for all organism-antibiotic cases. The top 50 resistance-associated features and top 50 susceptibility-associated features yielded by each threshold for each organism-antibiotic case were identified and combined into a single top feature set for each threshold; pairs of these top feature sets across different thresholds were compared by identifying what fraction of features were shared (selected under both thresholds), not shared (available under both thresholds but selected in only one), or differentially encoded (available under only one threshold and impossible to be shared) ([S5 Fig](#pcbi.1007608.s005){ref-type="supplementary-material"}).

Assessing enrichment for highly variable genes among selected features {#sec017}
----------------------------------------------------------------------

The total number of unique alleles observed for each core gene ("allele count") was computed for each species' pan-genome. For each organism-antibiotic case, the mean and median allele count of core genes for which at least one allele was selected by SVM-RSE to be associated with resistance ("selected core genes") was computed. This was compared to the mean and median allele count of all core genes for each species ([S6a and S6b Fig](#pcbi.1007608.s006){ref-type="supplementary-material"}). For each species, the full allele count distribution of selected core genes was compared to that of all core genes for the organism-antibiotic case with the largest difference in mean allele count between selected and all core genes ([S6c--S6e Fig](#pcbi.1007608.s006){ref-type="supplementary-material"}).

Assessing enrichment for plasmid genes among selected features {#sec018}
--------------------------------------------------------------

To identify which genetic features were located on plasmids, every contig in every genome assembly was compared to known plasmids in PLSDB (version 2019_10_07) \[[@pcbi.1007608.ref046]\] using MASH \[[@pcbi.1007608.ref058]\] set to a distance threshold of 0.01, i.e. contigs with distance \< 0.01 to a known plasmid were marked as plasmid contigs. All alleles found on plasmid contigs and all genes for which a majority of unique alleles were found on plasmid contigs were treated as plasmid features; all other features were treated as chromosomal. For each organism-antibiotic case, the number of plasmid and chromosomal features in the top 50 features selected by SVM-RSE was computed along with the odds ratio for plasmid features with respect to all features for that organism. As plasmid features are predominantly non-core genes, this calculation was also repeated for just non-core features to more accurately reflect enrichment for plasmid features ([S5 Table](#pcbi.1007608.s016){ref-type="supplementary-material"}).

Analysis of *gyrA* and *parC* mutations with respect to fluoroquinolone resistance {#sec019}
----------------------------------------------------------------------------------

The top 10 hits associated with either resistance (highest feature weights) or susceptibility (lowest feature weights) for the *S*. *aureus*-ciprofloxacin, *P*. *aeruginosa*-levofloxacin, and *E*.*coli*-ciprofloxacin cases were filtered down to just alleles of *gyrA* and *parC*. Mutations for these alleles were called relative to the corresponding protein sequence in the following reference genomes: N315 (NC_002745.2) for *S*. *aureus*, PAO1 (NC_002516.2) for *P*. *aeruginosa* and K12 MG1655 (U00096.3) for *E*. *coli*. Individual mutations for these alleles were compared to those known to confer resistance to FQs ([Table 3](#pcbi.1007608.t003){ref-type="table"}). Across all *gyrA* and *parC* alleles in each pan-genome, the most abundant alleles were selected (top 8 for *S*. *aureus* and *P*. *aeruginosa*, top 12 in *E*. *coli*) and the LOR for resistance to FQ was computed for each allele individually, as well as for each *gyrA*/*parC* pairing to identify potential interactions ([S7 Fig](#pcbi.1007608.s007){ref-type="supplementary-material"}). This pairwise interaction analysis was repeated for all pairs between the top 10 hits associated with resistance by SVM-RSE for the three FQ cases ([S8 Fig](#pcbi.1007608.s008){ref-type="supplementary-material"}).

Extracting candidate novel AMR determinants from SVM-RSE weights {#sec020}
----------------------------------------------------------------

For each of the 16 organism-antibiotic cases, the top 10 hits associated with resistance were filtered down to higher confidence candidates for novel AMR determinants using the following steps: Features already known to be associated with AMR were removed. Features annotated as transposases, phage proteins, or other mobile elements were also removed, as their function may be attributable to their position rather than just their presence or sequence. For core gene alleles, mutations were called relative to the corresponding gene in a reference genome (same as in the FQ case study), and only alleles with at least one mutation highly enriched for resistance were kept (\>95% of genomes with the mutation are resistant). These mutations were further characterized by their location in predicted domains or other structural features from InterPro ([Table 4](#pcbi.1007608.t004){ref-type="table"}, [Fig 4](#pcbi.1007608.g004){ref-type="fig"}); only mutations present in at least 5 genomes are shown. For non-core genes, the most common allele of the gene cluster was identified as the dominant allele, and genes with high sequence variability were filtered out to remove noisy gene calls (i.e. cases where \>10% of the instances of that gene have an edit distance \>10 from the dominant allele). Of the remaining non-core genes, the dominant alleles were annotated using InterProScan \[[@pcbi.1007608.ref051]\] and further filtered down to those with at least one domain annotation. LORs for both core gene alleles and non-core genes were computed using the method as for the curated *S*. *aureus* AMR genes.

Supporting information {#sec021}
======================

###### Core-genome size for each organism at different core gene thresholds.

For each pan-genome, the threshold for classifying a gene as a core gene was relaxed from allowing at most 0 to at most 50 genomes to be missing the gene. The threshold of 10 genomes used for subsequent analyses is shown.

(TIF)

###### 

Click here for additional data file.

###### Type and distribution of known AMR genes in the *S*. *aureus* pan-genome.

\(a\) Each known AMR gene detected in the *S*. *aureus* pan-genome was assigned to one of four broad mechanistic categories. For each allele of each known AMR gene, the number of genomes it is present in and the log2 odds ratio (LOR) for resistance against the appropriate drug was plotted, labeled by (b) drug or (c) mechanism.

(TIF)

###### 

Click here for additional data file.

###### Out-of-bag performance of individual SVMs in each SVM-RSE compared to null models.

For each of the 16 organism-antibiotic cases across (a) *S*. *aureus*, (b) *P*. *aeruginosa*, and (c) *E*. *coli*, the performance of each of the 500 constituent SVMs used in the corresponding SVM-RSE was assessed as the Matthew's correlation coefficients (MCCs) when predicting AMR phenotypes for out-of-bag genomes (those not used for training), shown in blue. The out-of-bag MCCs of constituent SVMs of SVM-RSEs trained using randomly shuffled AMR phenotype annotations are shown in orange.

(TIF)

###### 

Click here for additional data file.

###### Receiver operating curves of SVM-RSE models from 5-fold cross validation.

ROC curves for each of the 16 organism-antibiotic cases across (a) *S*. *aureus*, (b) *P*. *aeruginosa*, and (c) *E*. *coli*. The dark blue curves are mean ROC curves from 5-fold cross validation, the lighter curves are individual ROC curves corresponding to each fold, and the grayed areas are within one standard deviation of the mean ROC curve.

(TIF)

###### 

Click here for additional data file.

###### Consistency of selected features for different core gene thresholds.

The top 100 features (top 50 resistance-associated + top 50 susceptibility-associated) were identified using SVM-RSE for three different core gene thresholds (10: missing from at most 10 genomes, 10%: missing from at most 10% of all genomes, 2%: missing from at most 2% of all genomes). For each pair of thresholds, the fraction of shared vs. non-shared features in the union of their top 100 feature sets were computed. Non-shared features were classified as either "not shared", where both representations contain the feature, or "diff. coded", where the feature is only available under one of the thresholds.

(TIF)

###### 

Click here for additional data file.

###### Overall sequence variability of selected core gene alleles.

For each organism-antibiotic case, the distribution of the number of alleles of all core genes was compared to that of core genes for which at least one allele was selected by SVM-RSE to be associated with resistance or susceptibility. The (a) mean and (b) median of the selected core gene allele count is shown for each case, compared to the mean and median for all core genes of the corresponding species (dotted lines). For each species, the allele count distributions are shown for the case with the largest difference in mean allele count, (c) *S*. *aureus* vs. sulfamethoxazole/trimethoprim, (d) *P*. *aeruginosa* vs. amikacin, and (e) *E*. *coli* vs. ceftazidime.

(TIF)

###### 

Click here for additional data file.

###### Interactions between *gyrA* and *parC* alleles in fluoroquinolone resistance.

Log2 odds ratios (LORs) for fluoroquinolone resistance were calculated for each *gyrA/parC* allele pairing and compared to individual alleles in (a) *S*. *aureus*, (b) *P*. *aeruginosa*, and (c) *E*. *coli*. Each cell shows the number of resistant genomes with the allele above, the total number of genomes with the allele below, and is colored by LOR; row and column totals do not add up as only the top 8 (for *S*. *aureus* and *P*. *aeruginosa*) or top 12 (for *E*. *coli*) most frequently observed *gyrA* and *parC* alleles are shown. Alleles among the top 10 features detected by SVM-RSE to be associated with fluoroquinolone resistance are in red, while those the SVM-RSE associated with susceptibility are in blue.

(TIF)

###### 

Click here for additional data file.

###### Interactions between the top model-predicted hits for fluoroquinolone resistance.

For each of the top 10 genetic features predicted by SVM-RSE to be associated with fluoroquinolone resistance in (a) *S*. *aureus*, (b) *P*. *aeruginosa*, and (c) *E*. *coli*, log2 odds ratios (LORs) for resistance were computed for each feature individually as well as for every top feature pairing. Each cell shows the number of resistant genomes with the allele above, the total number of genomes with the allele below, and is colored by LOR. Gene features are denoted by either their gene name, reference genome locus tag, or "Cluster\_\#" in cases the coding sequence could not be confidently mapped to a known gene. Allele features are denoted as \"gene name-allele number". Features known to confer resistance are in red.

(TIF)

###### 

Click here for additional data file.

###### Comparison of gene frequency, diversity, and functional distributions in the *S*. *aureus*, *P*. *aeruginosa*, and *E*.*coli* pan-genomes.

\(a\) Distribution of genes categorized by frequency within each pan-genome: i) core: present in all genomes, ii) near-core: missing from at most 10 genomes, iii) accessory: missing from \>10 genomes and present in \>10 genomes, iv) near-unique: present in 2--10 genomes, v) unique: present in exactly 1 genome. (b) Estimation of pan-genome openness using Heap's Law. The total number of genes (pan-genome size) and number of genes in all genomes (core genome size) was computed as genomes were introduced sequentially from either the *S*. *aureus* (SA), *P*. *aeruginosa* (PA), or *E*. *coli* (EC) pan-genome. Each value represents the median from 2000 random permutations of genome order. The new gene rate (NGR) was fitted to Heap's Law, in which a more negative exponent represents a more closed pan-genome. (c) Log2 odds ratios (LORs) between individual functional categories and the core, accessory (acc), and unique genomes for each organism individually and combined.

(TIF)

###### 

Click here for additional data file.

###### Distribution of gene functions in the pan-genomes of *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*.

The distribution of gene functional categories based on Clusters of Orthologous Groups (COGs) in the core, accessory, and unique genomes are shown, either (a) including, or (b) excluding the "S: Function unknown" category.

(TIF)

###### 

Click here for additional data file.

###### Distribution of gene functions for different thresholds for core and unique genes.

For each organism, the set of genes in the (a) core genome was assembled for different core gene thresholds (the maximum number of genomes allowed to be missing a core gene), and (b) analogously for unique genes comprising the unique genome (the maximum number of genomes allowed to carry a unique gene). The "S: Function unknown" functional category is not shown.

(TIF)

###### 

Click here for additional data file.

###### Number of core, accessory, and unique genes and alleles in the pan-genome of each organism.

(DOCX)

###### 

Click here for additional data file.

###### AMR phenotypes of PATRIC genomes and corresponding typing methods and standards.

(DOCX)

###### 

Click here for additional data file.

###### Number of significant features associated with antimicrobial resistance in *S*. *aureus*, as detected by Fisher's exact tests and Cochran--Mantel--Haenszel tests.

(DOCX)

###### 

Click here for additional data file.

###### Aminoglycoside-modifying enzymes identified by sequence homology in the *P*. *aeruginosa* pan-genome compared to amikacin resistance phenotypes.

(DOCX)

###### 

Click here for additional data file.

###### Enrichment for plasmid over chromosomally encoded genetic features selected by SVM-RSE.

(DOCX)

###### 

Click here for additional data file.

###### Comparison of estimates for *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli* core-genome sizes.

(DOCX)

###### 

Click here for additional data file.

###### Fisher's exact test p-values between each COG functional category and the combined core, accessory, or unique genomes of *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli*.

(DOCX)

###### 

Click here for additional data file.

###### Fisher's exact test p-values between each COG functional category and the individual core, accessory, and unique genomes of *S*. *aureus* (SA), *P*. *aeruginosa* (PA), and *E*. *coli* (EC).

(DOCX)

###### 

Click here for additional data file.

###### PATRIC Genome IDs for *S*. *aureus*, *P*. *aeruginosa*, and *E*. *coli* genomes used in this study.

(XLSX)

###### 

Click here for additional data file.

###### Protein sequences for known AMR-conferring genes relevant to *S*. *aureus* analysis.

Contains representative protein sequences of genes known to be associated with resistance against ciprofloxacin, clindamycin, erythromycin, gentamicin, sulfamethoxazole, tetracycline, and trimethoprim. Files named \<drug\>\_card_amr.faa contain sequences that were extracted from the CARD database, retrieved November 26, 2018. File other_amr.faa contains additional sequences for AMR-conferring genes from literature and UniProt compiled independent of CARD.

(ZIP)

###### 

Click here for additional data file.

###### Protein sequences for the top 50 resistance-associated genetic features identified by SVM-RSE for each organism-antibiotic case.

Files are named \<organism\>\_\<antibiotic\>\_top_hits_seqs.faa, which each contain all protein sequences relevant to the top 50 hits of the corresponding organism-antibiotic case. For selected alleles, the exact protein sequence of the allele is included. For selected genes, the protein sequences of all alleles of that gene observed in the organism's pan-genome are included. The most commonly observed allele for selected genes is available in [S4 Dataset](#pcbi.1007608.s023){ref-type="supplementary-material"}.

(ZIP)

###### 

Click here for additional data file.

###### Annotations for the top 50 resistance-associated genetic features identified by SVM-RSE for each organism-antibiotic case.

Includes the following annotation for each genetic feature: 1) ranking from SVM-RSE, 2) the name of the common allele for selected genes, 3) locus tag of the best aligned reference sequence in the corresponding reference genome, if any, 4) gene name of the reference sequence, if available, 5) gene name assigned by eggNOG, if available, and 6) gene functional annotation by eggNOG. Additional details are available in the document.

(XLSX)

###### 

Click here for additional data file.

###### Additional figure-associated data.

Contains figure data in tabular format for Figs [1b, 1c](#pcbi.1007608.g001){ref-type="fig"}, [4](#pcbi.1007608.g004){ref-type="fig"}, [S2b, S2c](#pcbi.1007608.s002){ref-type="supplementary-material"}, [S5](#pcbi.1007608.s005){ref-type="supplementary-material"}, [S6a, S6b](#pcbi.1007608.s006){ref-type="supplementary-material"} and [S9c](#pcbi.1007608.s009){ref-type="supplementary-material"} Figs.

(XLSX)

###### 

Click here for additional data file.

###### References for [S6 Table](#pcbi.1007608.s017){ref-type="supplementary-material"}.

(DOCX)

###### 

Click here for additional data file.

###### Supplemental discussion of *S*. *aureus*, *P*. *aeruginosa*, *and E*. *coli* pan-genome properties.

(DOCX)

###### 

Click here for additional data file.

We thank Dr. Shankar Subramanian for helpful commentary on the evaluation of known resistance genes.
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Dear Dr Monk,

Thank you very much for submitting your manuscript \'Machine learning with random subspace ensembles identifies antimicrobial resistance determinants from pan-genomes of three pathogens\' for review by PLOS Computational Biology. Your manuscript has been fully evaluated by the PLOS Computational Biology editorial team and in this case also by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. While your manuscript cannot be accepted in its present form, we are willing to consider a revised version in which the issues raised by the reviewers have been adequately addressed. We cannot, of course, promise publication at that time.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Your revisions should address the specific points made by each reviewer. Please return the revised version within the next 60 days. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by email at <ploscompbiol@plos.org>. Revised manuscripts received beyond 60 days may require evaluation and peer review similar to that applied to newly submitted manuscripts.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A detailed list of your responses to the review comments and the changes you have made in the manuscript. We require a file of this nature before your manuscript is passed back to the editors.

\(2\) A copy of your manuscript with the changes highlighted (encouraged). We encourage authors, if possible to show clearly where changes have been made to their manuscript e.g. by highlighting text.

\(3\) A striking still image to accompany your article (optional). If the image is judged to be suitable by the editors, it may be featured on our website and might be chosen as the issue image for that month. These square, high-quality images should be accompanied by a short caption. Please note as well that there should be no copyright restrictions on the use of the image, so that it can be published under the Open-Access license and be subject only to appropriate attribution.

Before you resubmit your manuscript, please consult our Submission Checklist to ensure your manuscript is formatted correctly for PLOS Computational Biology: <http://www.ploscompbiol.org/static/checklist.action>. Some key points to remember are:

\- Figures uploaded separately as TIFF or EPS files (if you wish, your figures may remain in your main manuscript file in addition).

\- Supporting Information uploaded as separate files, titled Dataset, Figure, Table, Text, Protocol, Audio, or Video.

\- Funding information in the \'Financial Disclosure\' box in the online system.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see [here](http://journals.plos.org/ploscompbiol/s/submission-guidelines#loc-materials-and-methods). 

We are sorry that we cannot be more positive about your manuscript at this stage, but if you have any concerns or questions, please do not hesitate to contact us.

Sincerely,

Nicola Segata

Associate Editor

PLOS Computational Biology

Alice McHardy

Deputy Editor

PLOS Computational Biology

A link appears below if there are any accompanying review attachments. If you believe any reviews to be missing, please contact <ploscompbiol@plos.org> immediately:

\[LINK\]

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: In this submitted manuscript the authors (Hyun et al.) propose a method that predicts antimicrobial resistant (AMR) genes using SVM ensembles trained using random subspace ensemble (RSE). The SVM-RSE predictors were built for 3 of the main multi-drug resistant Bacterial species and 10 antibiotic classes extracting features from the 3 pan-genomes.

The authors show that the SVM-RSEs are more accurate in predicting AMR genes than well-established association tests. Furthermore the technique is reference-agnostic and has the potential to be improved further.

The manuscript is generally nice to read and has ample supporting material.

Following is a list of minor issues that I encountered reading the manuscript:

I\) In lines 229-231 the authors state that oversampling or undersampling did not affect the performance. this does not seem so clear from Fig3b, were ranks for SVM-RSE-O and SVM-RSE-U are sensibly higher than those given from SVM-RSE. Please rephrase accordingly or explain in more details.

II\) In figures (main and supplementary) change \"\# of X\" with \"Number of X\"

III\) In Fig. 1 it would be nice to have a more descriptive legend (e.g. near-core: missing from \<= 10 strains)

IV\) In Fig2a, specify the distance used in the y-axis

V\) In Fig2b and c, add a legend for the resistance patterns

VI\) Fig. S2, and S3: add \"Functional category\" above the legends

VII\) Lines 173-175: there is probably a missing/wrong word in the sentence (e.g. \"or are involved efflux span\", please fix it.

VIII\) Fig 3b: in the x-axis change \"ImsR\" with \"ImrS\"

Reviewer \#2: In this work, Hyun et al. have developed a Support Vector Machine (SVM)-based method to identify and predict antimicrobial resistance determinants from (pan)genomic data.

First, they build pangenomes for three species of interest (S. aureus, P. aeruginosa and E. coli) and then they use such gene sets to train and apply models for AMR determinants search.

They succeed in the identification of known determinants and their method seems to outperform common association tests and to achieve prediction accuracies competitive with

previous machine learning approaches (although a proper and clear benchmarking is missing in the current submission). The paper is well written and the amount of data analyses is notable.

Overall I have a few concerns regarding the structure of the paper and the lack of experimental validation on some of the predictions.

\- The first part of the results is devoted to "standard" pangenomic analyses. It is no news that core and accessory gene sets do not show interesting and significantly enriched COG categories. Those categories are to broad, especially for the purpose of the current analysis. I would suggest to move the first paragraph ("Analysis of genetic diversity in S. aureus, P. aeruginosa, and E. coli pan-genomes") to SM and start the Results section from the current "Support vector machine ensembles identify known AMR genes more...".This would allow going straight to the point.

\- It is interesting that the SVM-RSE method identifies novel putative AMR determinants. This, however, calls for an experimental validation of the capability of a few of such genes (ideally one for each of the species) to confer resistance to the organism harboring them. This would render the manuscript and the implemented approach much more reliable. Do those substitutions confer resistance to otherwise susceptible strains? Additionally, hflX or oppD are ideal targets to validate the predictions made by the authors.

\- I have a (minor) concern about the criterion used to classify a gene into core, near-core, accessory, unique or near-unique. The authors have shown a threshold based on a fixed number of strains (10, page 18, from line 410). However, the genome datasets are highly variable among the selected species (288, 456, and 1588 publicly-available genomes for S. aureus, P. aeruginosa, and 96 E. coli, respectively) so I think It would be worth replacing such a fixed threshold with a relative amount (10%?). I would be curious to see whether the numbers and the results would change applying such a relative criterion.

Reviewer \#3: Hyun and colleagues provide a novel machine learning-based approach for finding enriched sets of alleles involved in AMR. These are compared to known AMR gene alleles, and some discussion is provided for the genes that are implicated by the models that were previously unrecognized in these species. The paper is well written and I enjoyed reading it. However, there were several places in the manuscript where I became very confused. In my opinion text requires a major revision that centers on clarifying certain points, and directly focusing on the message of the paper. That being said, I think that it is scientifically sound and that this paper will be of importance to readers.

Here are my comments:

In the intro, has this RSE approach been used with success elsewhere? Was the choice inspired in some way or invented by the authors?

The last paragraph of the intro, line 88, says that RSEs aggregate classifiers trained on random subsets of both the sample set and the feature set. This requires a sentence explaining what the sample set and feature set are in this context. At first I thought samples were genomes, but since this is a study of pan genomes that was not clear (at this point in the paper).

Figure 1a says strains, but I think the authors mean genomes since two genomes of the same strain could exist in the training set.

Did the authors do anything to account for the phylogenetic distribution of the strains of each species?

Step 4 of figure 3a says "Train SVMs on AMR phenotypes, average weights". I can't find exactly how the authors processed the AMR phenotypes. In the case of MICs, are they predicting MICs? Was everything converted to susceptible vs. resistant, S vs. I vs. R, susceptible vs. non-susceptible etc. If so, did they use CLSI or EUCAST?

Similarly, this looks like they built an ensemble of SVMs for predicting the key features for one antibiotic at a time, analyzing one species at a time, but that also is not clear until you get very deep into the paper and it is not made clear in the methods.

For any core gene, each mutational variant observed would create another dimension in the vector. Some important core genes would be expected to have very few variants and hence dimensions, and some might have many. Do the authors have any insights on how this might affect accuracy or the ultimate selection of AMR-related features in either a regular SVM or a RSE? Are the important genes, simply those that have few variants?

Coloring and/or scale should be defined in Figure 1c.

The authors use the term allele, throughout, which I believe means alternative forms of the same gene. However, on line 166 they jump to protein space by defining alleles based on blastp. Is the feature vector based on proteins or genes? I think it is proteins. They should clarify, and I recommend careful use of terms here. This also makes Table 3 a bit confusing because I think the table is describing nucleotide SNPs in column 2 (ie. gene space), but I don't understand how the model is identifying a nucleotide here if it is based on proteins.

Along these lines, the results section starting on line 181 sets up a comparison of statistical tests vs. the SVM method. Some lead in is required here. I think that the authors are performing statistics over the same matrix that they are performing the svm analysis but that isn't clear in the text.

Based on my recollection, I think that set of antimicrobials and their associated alleles for the 3 species tends to skew toward chromosomally encoded AMR genes (Lines 162-165). Is that the case? I don't think that action is required in terms of the experimental approach but that should be mentioned, with some discussion of implications, if it is indeed true.

In figure 2A and B I don't understand how the data can cluster if there is no information on susceptible vs. resistant phenotypes (2B) for many of the strains in the purple clade on the right-hand side of the plot. Were the purple strains used in the model?

The rationale for the computation of pan-genome openness (line 120) and its depiction in Figure 1 and the supplemental figure are not entire clear to me. If it is required, please clarify. If not, it might help the paper if this went in the supplement. This is also true of the extensive examination of overlap in function between core and accessory genes. This is important but not of primary importance, unless I have missed something.

The authors previously wrote a really nice paper on M. tuberculosis (ref 6). Why was this organism excluded from the analysis? Is there something different about this organism that makes it less amenable to the method?

I understand that shifting from an optimization for model accuracy to a focus on gene identification is important, but the accuracy of the models should still be described in greater detail. It only appears on line 265. I think that the precision vs. recall data are still important to this study because they will provide information that the models are correctly balanced and capable of predicting both classes accurately. This in turn lends support to the idea that we should believe the feature list that has been implicated in AMR. To this end, I think that Figure S4 (counts of SR genomes) and S7 (Accuracy vs MCC) should be brought back into the main text, and that either precision and recall, or F1 should be showed as well.

It seems like this method casts a wide net. That is, the top features are enriched by known AMR variants, but that there is still a lot of genes that are being pulled in and that some analysis is required to determine their biological relevance. It would be nice to get these lists. It would bring interest to the bench scientists.

Small things:

Line 154 define DHFR

Line 249, I think the authors mean trimethoprim/sulfamethoxazole, but I'm not 100% sure.

Line 265 "an accuracies"

In Dataset S1, the underscores in the PATRIC ids should be converted to periods, or a table legend is required. Might be good to convert cells to text format first.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: No: I couldn\'t find spreadsheets for most of the figures in this submission (e.g Fig. 1C, 2B \...)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No
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16 Dec 2019

Dear Dr Monk,

We are pleased to inform you that your manuscript \'Machine learning with random subspace ensembles identifies antimicrobial resistance determinants from pan-genomes of three pathogens\' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pcompbiol/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process.

One of the goals of PLOS is to make science accessible to educators and the public. PLOS staff issue occasional press releases and make early versions of PLOS Computational Biology articles available to science writers and journalists. PLOS staff also collaborate with Communication and Public Information Offices and would be happy to work with the relevant people at your institution or funding agency. If your institution or funding agency is interested in promoting your findings, please ask them to coordinate their releases with PLOS (contact <ploscompbiol@plos.org>).

Thank you again for supporting Open Access publishing. We look forward to publishing your paper in PLOS Computational Biology.

Sincerely,

Nicola Segata

Associate Editor

PLOS Computational Biology

Alice McHardy

Deputy Editor

PLOS Computational Biology

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The minor issues found in the original version of the manuscript have been solved.

The readability of the manuscript has been considerably improved and we are confident that this scientifically sound manuscript would be of interest of the readers of PLoS Computational Biology.

Reviewer \#3: The authors have carefully addressed my concerns. As I said in the initial review, I enjoyed reading it. I\'m looking forward to citing this work.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: No
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